Nisa Investment Advisors
CTMX icon

Nisa Investment Advisors’s CytomX Therapeutics CTMX Stock Holding History

Nisa Investment Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,245
Closed -$2K – 2589
2022
Q2 		$2K Hold
1,245
– – ﹤0.01% 2342
2022
Q1 		$3K Hold
1,245
– – ﹤0.01% 2330
2021
Q4 		$6K Hold
1,245
– – ﹤0.01% 2074
2021
Q3 		$6 Hold
1,245
– – ﹤0.01% 2246
2021
Q2 		$8 Hold
1,245
– – ﹤0.01% 2246
2021
Q1 		$10 Hold
1,245
– – ﹤0.01% 2208
2020
Q4 		$8K Buy
1,245
+550
+79% +$3.93K ﹤0.01% 2236
2020
Q3 		$5K Hold
695
– – ﹤0.01% 2194
2020
Q2 		$6K Buy
+695
New +$6.45K ﹤0.01% 1993

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nisa Investment Advisors's CTMX Position: Q3 2022 in Review

Nisa Investment Advisors sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 1,245 shares — an estimated $2K sold.

Nisa Investment Advisors first reported a position in CTMX in Q2 2020 and held it in 9 quarters. The position peaked at $8K in Q4 2020. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • Nisa Investment Advisors reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,245 CytomX Therapeutics shares in Q3 2022, an estimated $2K.
  • Nisa Investment Advisors first reported a position in CytomX Therapeutics in Q2 2020 and held it in 9 quarters.
  • Nisa Investment Advisors's CytomX Therapeutics position peaked at $8K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on Nisa Investment Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.